spacer
spacer

PDBsum entry 1pxx

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Oxidoreductase PDB id
1pxx

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
552 a.a. *
Ligands
NAG-NAG-NAG ×4
NAG ×8
BOG ×2
HEM ×4
DIF ×4
Waters ×317
* Residue conservation analysis
PDB id:
1pxx
Name: Oxidoreductase
Title: Crystal structure of diclofenac bound to the cyclooxygenase active site of cox-2
Structure: Prostaglandin g/h synthase 2. Chain: a, b, c, d. Synonym: cyclooxygenase-2, cox-2, prostaglandin-endoperoxide synthase 2, prostaglandin h2 synthase 2, pgh synthase 2, pghs-2, phs ii, glucocorticoid-regulated inflammatory cyclooxygenase, gripghs, tis10 protein, macrophage activation-associated marker protein p71/73, pes- 2. Engineered: yes
Source: Mus musculus. House mouse. Organism_taxid: 10090. Gene: ptgs2 or cox2 or cox-2 or tis10 or pghs-b. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: sf9.
Biol. unit: Dimer (from PQS)
Resolution:
2.90Å     R-factor:   0.254     R-free:   0.302
Authors: J.R.Kiefer,S.W.Rowlinson,J.J.Prusakiewicz,J.L.Pawlitz,K.R.Kozak, A.S.Kalgutkar,W.C.Stallings,L.J.Marnett,R.G.Kurumbail
Key ref:
S.W.Rowlinson et al. (2003). A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem, 278, 45763-45769. PubMed id: 12925531 DOI: 10.1074/jbc.M305481200
Date:
07-Jul-03     Release date:   09-Sep-03    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
Q05769  (PGH2_MOUSE) -  Prostaglandin G/H synthase 2 from Mus musculus
Seq:
Struc:
 
Seq:
Struc:
604 a.a.
552 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.1.14.99.1  - prostaglandin-endoperoxide synthase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: (5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + 2 O2 = prostaglandin H2 + A + H2O
(5Z,8Z,11Z,14Z)-eicosatetraenoate
+ AH2
+ 2 × O2
= prostaglandin H2
+
+ H2O
Bound ligand (Het Group name = HEM)
matches with 51.11% similarity
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
DOI no: 10.1074/jbc.M305481200 J Biol Chem 278:45763-45769 (2003)
PubMed id: 12925531  
 
 
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
S.W.Rowlinson, J.R.Kiefer, J.J.Prusakiewicz, J.L.Pawlitz, K.R.Kozak, A.S.Kalgutkar, W.C.Stallings, R.G.Kurumbail, L.J.Marnett.
 
  ABSTRACT  
 
A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin G2 by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases. Several modes of inhibitor binding in the COX active site have been described including ion pairing of carboxylic acid containing inhibitors with Arg-120 of COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2 side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530 chelate polar or negatively charged groups in arachidonic acid and aspirin. We tested the generality of this binding mode by analyzing the action of a series of COX inhibitors against site-directed mutants of COX-2 bearing changes in Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated by the S530A mutation. Determination of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and Ser-530. This finding represents the first experimental demonstration that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzyme in an orientation that precludes the formation of a salt bridge with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in time-dependent inhibition by nimesulide and piroxicam.
 
  Selected figure(s)  
 
Figure 1.
FIG. 1. COX substrate binding modes. Stereo diagram of the inhibitory binding mode of arachidonic acid to COX-2 (blue) aligned with the productive binding mode, observed in COX-1 (beige). The substrate is nominally rotated 180° between the two orientations, resulting in different coordination of the carboxylic acid group. Amino acids shown are within van der Waals contact of diclofenac except for Arg-120, Val-434, and Arg-513, added for reference. Red text indicates the position of the three amino acid differences between COX-1 and COX-2 within the active site. The superposition was performed using amino acids 113-122, 344-355, 385-391, and 522-532 and coordinate Protein Data Bank files 1CVU [PDB] and 1DIY [PDB] . All molecular graphics were generated with Ribbons and rendered with POV-Ray (36).
Figure 6.
FIG. 6. Comparison of inhibitor binding to COX-2. a, superposition of the structures of diclofenac (green) and indomethacin (gold carbons; Protein Data Bank number 4COX [PDB] ) shows their differential coordination to the protein, despite their comparable size and chemical composition. b, overlay of the structures of diclofenac and the inhibitory mode of arachidonic acid binding. Both ligands coordinate their acidic groups with the side chains of Tyr-385 and Ser-530 despite their dissimilar chemical structures.
 
  The above figures are reprinted by permission from the ASBMB: J Biol Chem (2003, 278, 45763-45769) copyright 2003.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21365086 E.Parisini, P.Metrangolo, T.Pilati, G.Resnati, and G.Terraneo (2011).
Halogen bonding in halocarbon-protein complexes: a structural survey.
  Chem Soc Rev, 40, 2267-2278.  
21276131 J.F.Standing, D.Tibboel, R.Korpela, and K.T.Olkkola (2011).
Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years.
  Paediatr Anaesth, 21, 316-324.  
21328404 V.Hähnke, A.Klenner, F.Rippmann, and G.Schneider (2011).
Pharmacophore alignment search tool: influence of the third dimension on text-based similarity searching.
  J Comput Chem, 32, 1618-1634.  
20564576 S.Alcaro, A.Artese, M.Botta, A.T.Zizzari, F.Orallo, F.Ortuso, S.Schenone, C.Brullo, and M.Yáñez (2010).
Hit identification and biological evaluation of anticancer pyrazolopyrimidines endowed with anti-inflammatory activity.
  ChemMedChem, 5, 1242-1246.  
20237816 S.Bouaziz-Terrachet, A.Toumi-Maouche, B.Maouche, and S.Taïri-Kellou (2010).
Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study.
  J Mol Model, 16, 1919-1929.  
20830700 S.L.Regan, J.L.Maggs, T.G.Hammond, C.Lambert, D.P.Williams, and B.K.Park (2010).
Acyl glucuronides: the good, the bad and the ugly.
  Biopharm Drug Dispos, 31, 367-395.  
20470236 T.J.Gan (2010).
Diclofenac: an update on its mechanism of action and safety profile.
  Curr Med Res Opin, 26, 1715-1731.  
19433337 C.E.Rogge, W.Liu, R.J.Kulmacz, and A.L.Tsai (2009).
Peroxide-induced radical formation at TYR385 and TYR504 in human PGHS-1.
  J Inorg Biochem, 103, 912-922.  
19347867 D.Zhao, X.Zhang, Y.Guo, W.Tan, and D.Lin (2009).
Cyclooxygenase-2 Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamous-cell carcinoma.
  Mol Carcinog, 48, 934-941.  
19894761 G.Wu, A.L.Tsai, and R.J.Kulmacz (2009).
Cyclooxygenase competitive inhibitors alter tyrosyl radical dynamics in prostaglandin H synthase-2.
  Biochemistry, 48, 11902-11911.  
19301318 P.Tosco, and L.Lazzarato (2009).
Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin.
  ChemMedChem, 4, 939-945.  
  20221336 V.F.Roche (2009).
A receptor-grounded approach to teaching nonsteroidal antiinflammatory drug chemistry and structure-activity relationships.
  Am J Pharm Educ, 73, 143.  
18727161 V.Hähnke, B.Hofmann, T.Grgat, E.Proschak, D.Steinhilber, and G.Schneider (2009).
PhAST: pharmacophore alignment search tool.
  J Comput Chem, 30, 761-771.  
18811827 B.J.Anderson (2008).
Paracetamol (Acetaminophen): mechanisms of action.
  Paediatr Anaesth, 18, 915-921.  
19032726 J.F.Standing, R.F.Howard, A.Johnson, I.Savage, and I.C.Wong (2008).
Population pharmacokinetics of oral diclofenac for acute pain in children.
  Br J Clin Pharmacol, 66, 846-853.  
  18302793 L.W.Padgett, A.C.Howlett, and J.Y.Shim (2008).
Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor.
  J Mol Signal, 3, 5.  
18038897 A.M.Ali, G.E.Saber, N.M.Mahfouz, M.A.El-Gendy, A.A.Radwan, and M.A.Hamid (2007).
Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors.
  Arch Pharm Res, 30, 1186-1204.  
18159230 A.Peretz, N.Degani-Katzav, M.Talmon, E.Danieli, A.Gopin, E.Malka, R.Nachman, A.Raz, D.Shabat, and B.Attali (2007).
A tale of switched functions: from cyclooxygenase inhibition to m-channel modulation in new diphenylamine derivatives.
  PLoS ONE, 2, e1332.  
17131340 F.Ahmed, S.Adsule, A.S.Ali, S.Banerjee, S.Ali, S.Kulkarni, S.Padhye, and F.H.Sarkar (2007).
A novel copper complex of 3-benzoyl-alpha methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway.
  Int J Cancer, 120, 734-742.  
18156036 V.Strand (2007).
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
  Lancet, 370, 2138-2151.  
17868110 W.Lim, S.Lee, I.Kim, M.Chung, M.Kim, H.Lim, J.Park, O.Kim, and H.Choi (2007).
The anti-inflammatory mechanism of 635 nm light-emitting-diode irradiation compared with existing COX inhibitors.
  Lasers Surg Med, 39, 614-621.  
16401081 C.E.Rogge, B.Ho, W.Liu, R.J.Kulmacz, and A.L.Tsai (2006).
Role of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2.
  Biochemistry, 45, 523-532.  
16552142 N.Singh, T.Jabeen, S.Sharma, R.K.Somvanshi, S.Dey, A.Srinivasan, and T.P.Singh (2006).
Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution.
  Acta Crystallogr D Biol Crystallogr, 62, 410-416.
PDB code: 2b17
17071117 S.Bingham, P.J.Beswick, D.E.Blum, N.M.Gray, and I.P.Chessell (2006).
The role of the cylooxygenase pathway in nociception and pain.
  Semin Cell Dev Biol, 17, 544-554.  
16149114 C.Drahl, B.F.Cravatt, and E.J.Sorensen (2005).
Protein-reactive natural products.
  Angew Chem Int Ed Engl, 44, 5788-5809.  
15626708 C.J.daCosta, D.E.Kaiser, and J.E.Baenziger (2005).
Role of glycosylation and membrane environment in nicotinic acetylcholine receptor stability.
  Biophys J, 88, 1755-1764.  
17191953 R.G.Huff, E.Bayram, H.Tan, S.T.Knutson, M.H.Knaggs, A.B.Richon, P.Santago, and J.S.Fetrow (2005).
Chemical and structural diversity in cyclooxygenase protein active sites.
  Chem Biodivers, 2, 1533-1552.  
15865061 G.Ermondi, G.Caron, R.Lawrence, and D.Longo (2004).
Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
  J Comput Aided Mol Des, 18, 683-696.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer